Additionally, when comparing incretin-treated patients to patients without diabetes, we found a significantly higher coma recovery rate in the incretin group post matching (76.26% vs. 64.75%, 95% CI for the difference 2.0–21.0%, P = 0.0272) (Fig. 2b). This evidence concerns the gene GCG and diabetes mellitus.